We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04442230
Recruitment Status : Terminated (Enrollment)
First Posted : June 22, 2020
Results First Posted : April 4, 2022
Last Update Posted : April 4, 2022
Information provided by (Responsible Party):
Altimmune, Inc.

Brief Summary:
The purpose of this study is to evaluate the safety and effectiveness of NasoVAX in preventing worsening of symptoms and hospitalization in patients with early COVID-19.

Condition or disease Intervention/treatment Phase
Coronavirus Infection Biological: NasoVAX Other: Placebo Phase 2

Detailed Description:

After being informed about the study and potential risks, all patient volunteers that have given written informed consent will undergo screening to determine eligibility for study entry. If the patient qualifies for the study, they will be randomized in a double-blind manner in a 1:1 ratio to receive NasoVAX or placebo. On the same day of qualifying into the study, the patient will be administered the investigational drug (either NasoVAX or placebo).

The patient will return home for the remainder of the study. During this period, the patient will be monitored remotely by the study center for clinical status. The patient will also be contacted by study center personnel by telephone to ask about use of any medications and changes in health including information about any hospitalization.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Masking Description: Double-Blind
Primary Purpose: Treatment
Official Title: Phase 2, Double-blind, Randomized, Placebo-controlled Study of NasoVAX in the Prevention of Clinical Worsening in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)
Actual Study Start Date : October 10, 2020
Actual Primary Completion Date : February 15, 2021
Actual Study Completion Date : February 15, 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: NasoVAX
Participants will receive a single intranasal dose of NasoVAX on Day 1 (enrollment).
Biological: NasoVAX
NasoVAX consists of replication-deficient adenovirus vectors in suspension

Placebo Comparator: Placebo
Participants will receive a single intranasal dose of placebo on Day 1 (enrollment).
Other: Placebo
Normal saline

Primary Outcome Measures :
  1. Percentage of Patients With Clinical Worsening [ Time Frame: Day 1 to Day 14 ]
    Absolute 4.0% decrease from baseline in resting SpO2 on two consecutive measurements

Secondary Outcome Measures :
  1. Maximal Severity of COVID-19 After Treatment [ Time Frame: Day 1 to Day 42 ]
    Percentage of patients requiring hospitalization

  2. All-cause Mortality [ Time Frame: Day 1 to Day 42 ]
    All-cause mortality through Day 42

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Able and willing to provide informed consent (Patients themselves must provide written informed consent before the performance of any study-related procedures, and surrogate consent by family members, designated legal representatives or caregivers will not be permitted).
  2. Men and women 18 years of age and older
  3. Early COVID-19, defined as one or more symptom(s) of fever (oral temperature ≥ 100.4 degrees F), cough, or shortness of breath, onset of these symptoms within 72 hours of screening, and confirmation of SARS-CoV-2 infection by a polymerase chain reaction (PCR)-based or rapid antigen diagnostic.
  4. Resting SpO2 ≥ 96.0% on room air on two successive measurements
  5. For women of childbearing potential (women who are not permanently sterile [documented hysterectomy, bilateral tubal ligation, salpingectomy, or oophorectomy] or postmenopausal [12 months with no menses without an alternative medical cause])

    • Negative urine pregnancy test at Screening
    • Willingness to practice a highly effective method of contraception that includes, but is not limited to, abstinence, sex only with persons of the same sex, monogamous relationship with a postmenopausal partner, monogamous relationship with vasectomized partner, vasectomy, licensed hormonal methods, intrauterine device, or consistent use of a barrier method (eg, condom, diaphragm) with spermicide for 28 days after the last dose of study drug
  6. For men with sexual partners of childbearing potential, willingness to practice a highly effective method of contraception, as defined above, for 45 days after the last dose of study drug
  7. Ability and willingness to comply with all aspects of the study, including reliable internet access, through the entire study period

Exclusion Criteria:

  1. Pregnant or lactating women or planning to conceive a child during the next 3 months
  2. Resting respiratory rate >20 breaths/min on room air or resting pulse rate ≥ 125 beats per minute
  3. A rapidly worsening course that in the opinion of the Investigator or treating medical practitioner would lead to hospitalization within the next 24-48 hours
  4. Any chronic pulmonary disease, including chronic obstructive pulmonary disease and asthma, or other respiratory diseases that could exacerbate independent of COVID-19
  5. The following risk factors for severe COVID-19 (Cohorts 1 and 2 only) (Centers for Disease Control 2020), which based on ongoing review of efficacy and safety data, the DMC may remove part or all of these risk factors if preliminary data show no signal for adverse or paradoxical effects:

    1. Severe obesity, defined as body mass index ≥ 40 kg/m2
    2. History of:

      • Severe cardiovascular disease, including but not limited to congestive heart failure, coronary artery disease, congenital heart disease, cardiomyopathies, or pulmonary hypertension
      • Diabetes mellitus
      • Chronic or current vaping or cigarette smoking
      • Chronic kidney disease requiring dialysis
      • Chronic liver disease, including but not limited to chronic viral hepatitis, non-alcoholic steatohepatitis, or cirrhosis of any cause
      • Hemoglobin disorder, including sickle cell disease and thalassemia
  6. History of Bell's Palsy
  7. Nasal conditions that might affect the suitability of intranasal medication, such as a history of chronic rhinitis, nasal septal defect, cleft palate, nasal polyps, or nasal surgery other than cosmetic rhinoplasty.
  8. Use of hydroxychloroquine within the past 4 months, chloroquine with the past 9 months, or other investigational agents for COVID-19 within the past 30 days
  9. History of conditions associated with immunocompromise, including but not limited to poorly controlled HIV, or treatments known to affect the immune system, including but not limited to oral or intravenous corticosteroids, alkylating drugs, antimetabolites, cytotoxic drugs, radiation, immune-modulating biologics (including interleukin [IL]-6, IL-12, Janus kinase inhibitors or antagonists), and cancer treatments, within 30 days of Screening, or anticipated use within 6 months following participation in this study
  10. Any medical, psychiatric, or social condition or occupational or other responsibility that in the judgment of the Investigator would interfere with or serve as a contraindication to protocol adherence, assessment of safety (including reactogenicity), or a patient's ability to give informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04442230

Layout table for location information
United States, Florida
Miami Dade Medical Research Institute
Miami, Florida, United States, 33176
United States, Georgia
Infinite Clinical Trials
Morrow, Georgia, United States, 30260
United States, Illinois
Cedar Crosse Research Center
Chicago, Illinois, United States, 60607
United States, North Carolina
Carolina Institute for Clinical Research
Fayetteville, North Carolina, United States, 28303
United States, Texas
Next Level Urgent Care
Houston, Texas, United States, 77057
Centex Studies
Houston, Texas, United States, 77058
Centex Studies
McAllen, Texas, United States, 78504
Sponsors and Collaborators
Altimmune, Inc.
  Study Documents (Full-Text)

Documents provided by Altimmune, Inc.:
Study Protocol  [PDF] January 4, 2021
Statistical Analysis Plan  [PDF] July 28, 2020

Layout table for additonal information
Responsible Party: Altimmune, Inc.
ClinicalTrials.gov Identifier: NCT04442230    
Other Study ID Numbers: ALT-601-201
First Posted: June 22, 2020    Key Record Dates
Results First Posted: April 4, 2022
Last Update Posted: April 4, 2022
Last Verified: February 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Altimmune, Inc.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronavirus Infections
Communicable Diseases
Respiratory Tract Infections
Pneumonia, Viral
Virus Diseases
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Disease Attributes
Pathologic Processes